Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Collaboration Needed To Ensure Access To Orphan Drugs – Express Scripts Exec

This article was originally published in The Pink Sheet Daily

Executive Summary

In an effort to ensure that there is access to high-priced drugs that treat rare diseases, relevant stakeholders, including manufacturers, payers, patients and physicians, need to come together and collaborate on access solutions that meet the needs of all parties, Express Scripts VP of Pharma Strategies and Account Management Bill Martin tells NORD/DIA conference.

You may also be interested in...

Rare Disease Drugs Deserve Lower Cost Sharing In Part D, McClellan Says

In a speech to an Oct. 24 conference on rare diseases and orphan drugs, former CMS Administrator Mark McClellan said drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies, which typically require coinsurance of 25% to 33%.

Pricing Rare Disease Drugs Requires Care As Payers Increase Scrutiny

Value questions are expected to be asked by payers and others as larger pharma companies enter the orphan drug space and more treatments debut targeting rare diseases.

Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year

Alexion Pharmaceuticals is launching its paroxysmal nocturnal hemoglubinuria Soliris (eculizumab) with a treatment support service with case managers to help facilitate reimbursement


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts